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Patients with long-standing ulcerative colitis (UC) are known to have an increased risk for the development of colorectal cancer
(CRC). The aim of this study was to clarify the cumulative risk for the development of dysplasia or invasive cancer and the
effectiveness of surveillance colonoscopy in the Japanese population. A total of 217 patients received a total of 1027 surveillance
colonoscopies between January 1979 and December 2001 at the University of Tokyo hospital. Patients with invasive cancer found in
the surveillance group were compared to those referred to our hospital from the other hospitals without surveillance colonoscopy.
Surveillance colonoscopy confirmed 15 patients with definite dysplasia. Of these, five were proved to have invasive cancer in the
resected specimens. The cumulative risk for the development of invasive cancer at 10, 20, and 30 years was 0.5, 4.1, and 6.1%,
respectively, while that for the development of definite dysplasia at 10, 20, and 30 years was 3.1, 10.0, and 15.6%, respectively. All the
patients with invasive cancer in the surveillance group remained alive, while three out of four patients in the nonsurveillance group
died. Our surveillance programme is useful for detecting UC-associated CRC, and survival may be improved by surveillance
colonoscopy.
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Patients with long-standing ulcerative colitis (UC) are known to
have an increased risk for the development of colorectal cancer
(CRC) (Ekbom et al, 1990) The recent meta-analysis study
reported that the cumulative risk of developing CRC is estimated
as 2% by 10 years, 8% by 20 years, and 18% by 30 years in patients
with UC (Eaden et al, 2001). Ulcerative colitis-associated CRC is
different from sporadic CRC in several ways. Patients with UC-
associated CRC are younger than those with sporadic CRC, and
even children are at risk for CRC in UC patients (Eaden et al,
2001). In addition, UC-associated CRC tends to be widespread and
is difficult to detect by colonoscopy (Morson and Pang, 1967).
Therefore, a specific surveillance programme should be established
for patients with long-standing UC. The well-known risk factors
for UC-associated CRC are the duration and extent of disease
(Gyde et al, 1988; Ekbom et al, 1990; Leidenius et al, 1991). It is
generally accepted that patients with total colitis for 8 years or
longer and those with left-sided colitis for 12–15 years or longer
should receive surveillance colonoscopy every 1 or 2 years in the
Western countries (Winawer et al, 1997; Farrell and Peppercorn,
2002) However, the effectiveness of such programmes is still
controversial (Lynch et al, 1993; Axon, 1994). In addition, the
cumulative risk for the development of dysplasia or cancer has not
been reported in the Asian populations. The aim of this study was
to clarify the cumulative risk for the development of dysplasia or
cancer and the effectiveness of surveillance colonoscopy for the
detection of UC-associated CRC in the Japanese population. Our
report outlines the results of a 23-year surveillance colonoscopy
programme for detecting CRC in long-standing UC in the Japanese
population, and as such, represents the first report of its kind in
Japan.
MATERIAL AND METHODS
Patients’ selection
We performed a surveillance colonoscopy programme at the
University of Tokyo hospital over a period of 23 years between
January 1979 and December 2001. Surveillance colonoscopy was
performed annually from 7 years after the onset of symptoms for
patients suffering from total UC (proximal to the splenic flexure)
and left-sided UC (distal to the splenic flexure). In several patients,
surveillance colonoscopy scheduled for 7 years from the onset was
performed several months earlier than 7 years. Such patients were
included in this study. The extent of disease was defined with
macroscopic findings at colonoscopy. Patients with proctitis were
excluded from this study. Surveillance colonoscopy was also
performed for those who had undergone subtotal colectomy and Received 4 April 2003; revised 4 July 2003; accepted 4 July 2003
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Patients with known dysplasia or cancer at the time of referral
were excluded. Those without evidence of dysplasia at the time of
referral were entered into this programme.
The extent of disease was classified at the first surveillance
colonoscopy. If the observed extent was less extensive than
what had been observed previously, the greatest extent of
disease was used for classification of the extent. If the observed
extent had increased, it was defined as disease progression. A
total of 217 patients were retrospectively reviewed in this study
(surveillance group). In all, 123 patients with total UC (one patient
underwent IRA during surveillance because of intractable disease),
68 with left-sided UC (in 14 of whom the disease had progressed
to total colitis) and 27 with post-IRA were retrospectively
reviewed. A total of 1027 colonoscopies were performed for the
purpose of surveillance. During the same period, four patients,
who had not received surveillance colonoscopy and who had
been diagnosed at other hospitals as having symptomatic
invasive cancer, were referred to us for surgical treatment
(nonsurveillance group).
Surveillance colonoscopy
We offered patients annual total colonoscopy, preferentially during
the remission state. Biopsy specimens were taken from flat mucosa
at least every 10cm of the whole colorectum, and additional biopsy
specimens were taken from lesions with any remarkable endo-
scopic abnormalities such as those that were elevated and those
with colour changes.
Histopathology
Biopsy specimens were fixed with formalin and stained with
Haematoxylin and eosin, and graded as high-grade dysplasia
(HGD), low-grade dysplasia (LGD), indefinite for dysplasia (IND),
or negative for dysplasia according to the criteria of the
Inflammatory Bowel Disease/Dysplasia morphology study group
(Riddell et al, 1983).
Follow-up
Total proctocolectomy was performed when patients were found to
have HGD. We performed follow-up colonoscopy within 3 months
for patients with LGD or IND. Surgery was performed for patients
with persistent LGD or LGD with dysplasia-associated lesion or
mass. A well-defined elevated lesion resembling a sporadic
adenomatous polyp without dysplastic change of the surrounding
mucosa was treated as coincidental adenoma and polypectomy was
performed. Such lesions were not included in the category of
dysplasia in this study. Otherwise, annual colonoscopy was
performed.
Evaluation
The cumulative risk for dysplasia and invasive cancer in the
surveillance group was evaluated. Patients with invasive cancer in
both surveillance and nonsurveillance groups were reviewed in
terms of the age of onset, gender, duration of disease, Dukes’
classification, and survival.
Statistics
StatView software (SAS Institute Inc, Cary, NC, USA) was used for
statistical analyses. The cumulative dysplasia-free and cancer-free
rates were calculated by the Kaplan–Meier method.
RESULTS
Results of surveillance colonoscopy
High-grade dysplasia or LGD were detected in 15 patients through
our surveillance programme. Of these, twelve patients suffered
from total colitis. Two patients were status post-IRA, both of
whom had had total colitis preoperatively. Only one patient had
left-sided colitis. A summary of the results of the surveillance
colonoscopy is shown in Figures 1 and 2.
Six patients were found to have HGD at surveillance
colonoscopy, all of whom underwent colectomy. Four of
them had invasive cancer and two had HGD in the resected
specimens. Nine patients were found to have LGD at surveil-
lance colonoscopy. Of the three patients who underwent colect-
omy, one had invasive cancer and one had HGD. The other
patient was found to have flat LGD at surveillance colonoscopy,
and negative for dysplasia at the two following colonoscopies.
However, she preferred to undergo colectomy to close follow-up
colonoscopy, and no dysplasia was found in the resected speci-
mens. Two patients continued to receive surveillance colonoscopy
and no dysplasia was found after LGD was detected. Four patients
were lost to follow-up. Two of them had undergone operation
in other hospitals, and pathological reports were not available
for review.
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Figure 2 Results of surveillance colonoscopies in patients who were
found to have high-grade dysplasia or invasive carcinoma in resected
specimen.
217 UC
15 definite dysplasia
6 HGD*
6 surgery
4 CA 2 HGD 1 CA 1 HGD 1 NEG 2 NEG
3 surgery 2 continued follow-up 4 lost
9 LGD*
Figure 1 Summary of the results of a surveillance colonoscopy
programme in the Japanese population (*the highest degree of dysplasia
found in colonoscopy was used. CA¼invasive cancer; HGD¼high-grade
dysplasia; LGD¼low-grade dysplasia ; NEG¼negative for dysplasia).
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The cumulative dysplasia (HGD or LGD)-free survival curve and
cumulative cancer-free survival curve in patients with long-
standing UC in the surveillance group are shown in Figure 3.
The cumulative risk for the development of invasive cancer at 10,
20, and 30 years (95% confidence interval) was 0.5% (0–1.5), 4.1%
(0–8.3), and 6.1% (0.2–12.0), respectively, while that for the
development of definite dysplasia at 10, 20, and 30 years (95%
confidence interval) was 3.1% (0.6–5.6), 10.0% (4.3–15.7), and
15.6% (6.4–24.8), respectively.
Prognosis, surveillance group vs nonsurveillance group
The patients with invasive cancer in the surveillance group had
better prognoses than those in the nonsurveillance group. The
clinicopathological features in both groups are listed in Table 1.
Five patients in the surveillance group were found to have invasive
cancer. Dukes’ stages in the surveillance group were A in four and
B in one, whereas those in the nonsurveillance group were C in
three, and B in one. All the patients with invasive cancer in the
surveillance group remained alive, whereas three out of four
patients died. The mean postoperative follow-up period was 126
months (70–202), and 41 months (1–133) for the surveillance and
nonsurveillance group, respectively.
DISCUSSION
We performed a surveillance programme to detect UC-associated
CRC for 23 years, which we believe to be the first surveillance
programme reported in the Asian population. Our data suggest
that our surveillance programme was useful for detecting UC-
associated CRC, although the study was not performed in a
randomised manner and lead-time bias together with selection
bias could not be avoided. Some authors doubt whether
surveillance colonoscopy can detect UC-associated CRC earlier
and thereby improve the prognosis (Axon, 1994). However, it is
generally accepted that surveillance colonoscopy is important and
is the only way for detecting UC-associated CRC at this time
(Winawer et al, 1995). Therefore, this kind of study could not be
performed in a randomised manner.
Our programme successfully identified UC-associated CRC
at an earlier stage than other surveillance studies. Dukes’ stages
in the surveillance group were A in four and B in one, whereas
those in the nonsurveillance group were C in three patients and
B in one patient. It had been reported that patents with
UC-associated CRC at Dukes’ A and B showed a good
survival rate, but those at Dukes’ C showed an extremely
poor prognosis (Heimann et al, 1992). Our data are compatible
with that report. Patients with UC-associated CRC in the
surveillance group showed better prognoses than those in the
nonsurveillance group. All the patients in the surveillance group
remained alive, whereas three patients out of four in the
nonsurveillance group died. The duration of UC was approxi-
mately 5 years shorter in the surveillance group, and this could
result in lead-time bias. However, the follow-up period was
considered to be long enough to evaluate the prognoses. Since
all the patients basically underwent surveillance colonoscopy at
the time of referral or 7th year from the onset, it was difficult
to select an appropriate control group. In our series, several
patients refused further surveillance colonoscopy, but no such
patients have developed invasive cancer so far. Four patients,
who did not receive surveillance colonoscopy and were diagnosed
at other hospitals as having symptomatic invasive cancer, were
referred to us for the surgical treatment. These four were selected
as the control.
The cumulative risk of UC-associated CRC was calculated in
the surveillance group. There had been criticism that most of
the previous reports had statistical problems in calculating
the cumulative risk (Collins et al, 1987). In our series, patients
with UC-associated CRC or dysplasia referred from the other
hospitals were excluded to eliminate the bias. We believe this
report to be the first report in the Asian population. The
cumulative risk for invasive cancer in our series seems lower
than those reported in most of the Western countries (Biasco
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Figure 3 The cumulative definite dysplasia- and cancer-free survival rates
in patients with long-standing ulcerative colitis in the Japanese population.
Table 1 Clinicopathological features of the patients with ulcerative colitis-associated colorecal cancer
Case
Age of Onset
(years)
Age at operation
(years)
Duration
(years) Histology
a Depth Dukes Location
b Extent
c Survival
Surveillance group
4 16 37 21 mod,porXwell sm A R L Alive 7y5m
5 56 65 9 well to mod sm A S T Alive 5y10m
6 28 41 13 well sm A R T(IRA) Alive 16y10m
7 36 49 13 well mp A C T Alive 12y10m
8 21 41 20 well4mod4por ss B R T Alive 9y8m
Non surveillance group
23 44 21 well ss B D T Alive 11y1m
29 42 13 sig se C S T Dead 1y
20 40 20 muc4mod4por se C D T Dead 2y5m
29 47 18 sig se C D T Dead 1m
y¼years; m¼months.
amuc¼mucinous adenocarcinoma; well¼well differentiated adenocarcinoma; mod¼moderately differentiated adenocarcinoma; por¼poorly
differentiated adenocarcinoma; sig¼signet-ring cell carcinoma.
bR¼rectum; S¼sigmoid colon; D-descending colon; C¼caecum.
cT¼total colitis; L¼left-sided colitis.
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reported in Denmark, Czechoslovakia, and Israel (Nedbal and
Maratka, 1968; Gilat et al, 1974; Hendriksen et al, 1985). The
corresponding figure for dysplasia or cancer in our series is
almost identical to that reported in a very large series in the UK
(Lennard-Jones et al, 1990), and that for invasive cancer
calculated by meta-analysis (Eaden et al, 2001). These results
suggest that UC-associated cancer in the Japanese population
may be lower than that in most of the American and European
populations, but higher than that in Denmark, Czechoslovakia,
and Israel, although the confidence interval was wide in our series.
In our series, patients with total UC tended to have a higher risk
for developing HGD or invasive cancer than those with left-sided
colitis, but the difference was not statistically significant. Disease
extent is a confusing issue, since the definition is inconsistent. We
defined total colitis as colitis extending proximal to the splenic
flexure, and left-sided colitis as distal to it by macroscopic findings
at colonoscopy. We included proctosigmoiditis, but not proctitis in
the category of left-sided colitis.
Disease progression is another important issue. Previous studies
reported that a considerable number of patients with left-sided UC
experienced disease progression (Leijonmarck et al, 1990; Farmer
et al, 1993). In our series, 25 patients out of 137 (18%) with total
colitis were first regarded as being of the less extensive type. The
disease progressed from left-sided to total colitis after 7 years from
the onset in 14 of these patients. None of them has been found to
have dysplasia, so far. However, dysplasia or cancer would be
missed if left-sided colitis were excluded from the surveillance
programme. Connell et al (1994) also pointed out this ‘presumed
left-sided’ problem. In addition, it has been reported that the
cancer risk and the disease duration before the diagnosis of cancer
were the same in both total and left-sided colitis (Nugent et al,
1991; Sugita et al, 1991). Therefore, left-sided colitis should not be
totally excluded from the surveillance programme. However, the
optimum interval and starting point of surveillance for patients
with left-sided colitis should wait for cost-effectiveness studies of
the surveillance programme.
Our cases suggest that the starting point of surveillance
colonoscopy should be earlier than in previous reports. The
starting point in our series is 7 years. The guidelines of the World
Health Organization recommend that surveillance colonoscopy for
total colitis (extending at least to the hepatic flexure) should be
started from 8 years after the onset of symptoms, and that for left-
sided colitis (more distal involvement) it should be performed
from 12 to 15 years (Winawer et al, 1995). Other guidelines from
the American Journal of Gastroenterology recommend that
surveillance colonoscopy for both total and left-sided colitis
should be started from 8 to 10 years (Kornbluth and Sachar,
1997). Bernstein et al reported that 12% of the patients with long-
standing total colitis were found to have cancer or dysplasia at the
first surveillance colonoscopy in 10 surveillance programmes, and
concluded that dysplasia surveillance should be performed earlier
(Bernstein et al, 1994). In our series, two patients were found to
have dysplasia by colonoscopy within 7 years of onset. One patient
developed LGD 5 years and 8 months after onset (this patient was
not included in this study). Furthermore, serosal invasion was
found in the surgical specimen after an 8-month interval of
refusing colectomy against medical advice. In this case, refractory
disease and persistent anaemia made us promote surveillance
colonoscopy before 7 years after onset. In another patient,
surveillance colonoscopy that was performed several months
before reaching that point, but set for 7 years after the onset
revealed dysplasia, and the surgical specimen revealed HGD.
Surveillance colonoscopy starting from 7 years after onset might
have rescued the patient in the latter case, but not in the former
case. However, the cost would increase, if we started surveillance
colonoscopy from 5 years after onset.
The optimum frequency of surveillance colonoscopy is con-
troversial, but many reports adopted a 1-or-2-year interval. Annual
colonoscopy will double the cost but may increase sensitivity as
compared to the biannual colonoscopy. Moreover, we have to take
it into consideration that UC-associated CRC may advance faster
than sporadic CRC. The answer to this question should wait for the
cost–benefit analysis.
Some authors criticised poor compliance of the surveillance
colonoscopy. In our series, 109 patients continued receiving
surveillance colonoscopy, 20 underwent colectomy, 19 moved to
the other hospitals, 59 were lost to follow-up with reasons
unknown, nine refused colonoscopy, and one died of congestive
heart failure. In all, 30% of the patients failed to adhere to our
programme due to refusal or loss to follow-up. Compliance in our
series was not as good as that in the St Marks’ series (Connell et al,
1994). Further efforts need to be made to maintain good
compliance.
CONCLUSIONS
In what we believe to be the first series in the Asian population, we
performed a surveillance colonoscopy programme for long-
standing UC for 23 years, starting such surveillance earlier than
those reported previously, which successfully detect dysplasia or
cancer at an earlier stage.
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